Bipartisan legislation introduced this week by Senate Finance Committee Chairman Mike Crapo (R-ID) and Ranking Member Ron Wyden (D-OR) represents one of the strongest federal efforts yet to bring transparency and accountability to pharmacy benefit managers (PBMs).
The PBM Price Transparency and Accountability Act aims to address long-standing practices that have strained independent pharmacies, increased patient costs, and contributed to the rise of pharmacy deserts.
Key provisions include:
- Fair and transparent reimbursement for independent pharmacies under state Medicaid managed care
- Clear, enforceable CMS standards for Medicare Part D contract terms
- Strong bipartisan backing from Senate leadership and members across both parties
NCPA praised the legislation, emphasizing that PBM-driven reimbursement pressures continue to weaken community pharmacies nationwide. The bill represents a significant opportunity to strengthen access to local care and restore balance to the pharmacy ecosystem.
At StockMeds, we support efforts that improve fairness, transparency, and sustainability within the pharmacy industry. While legislative reforms progress, we remain focused on helping independent pharmacies strengthen their operations today — through improved access to inventory, new revenue opportunities, and tools that reduce reliance on volatile reimbursement structures.
Independent pharmacies deserve a stable, transparent landscape — and solutions that support them now and in the future.
— StockMeds Newsroom
